Erin Mandel1, Claire E Kendall2,3, Kate Mason4, Mary Guyton5, Bernadette Lettner4, Jennifer Broad4, Jason Altenberg4, Jessy Donelle6, Jeff Powis4,7. 1. Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario. 2. Department of Family Medicine, University of Ottawa, Ottawa, Ontario. 3. C.T. Lamont Primary Health Care Research Centre, Bruyere Research Institute, Ottawa, Ontario. 4. South Riverdale Community Health Centre, Toronto, Ontario. 5. Sherbourne Health, Toronto, Ontario. 6. ICES uOttawa, Ottawa, Ontario. 7. Michael Garron Hospital, Toronto, Ontario.
Abstract
Background: The majority of new hepatitis C (HCV) cases occur among people who inject drugs. In recent years, multidisciplinary models of HCV treatment have emerged that demonstrate successful treatment outcomes for this population, as well as broad positive individual- and system-level impacts. Our objective was to evaluate changes in health care use among a cohort of people living with HCV before and after engagement with one such program. Methods: Program data were uniquely linked to provincial health administrative databases. Rates of emergency department (ED) visits and hospital admissions of clients from 2011 through 2015 (N = 103) were evaluated using linkages with administrative data for the 2 years before and after program initiation. Data were evaluated using negative binomial regression models with a covariance structure to account for within-individual correlations. Results: Of participants, 72.8% were men (mean age 47 years), and 38% experienced high rates of physical and mental health comorbidity (Aggregated Diagnosis Group score ≥10). Female clients had significantly fewer ED visits 2 years after program initiation (5.04 versus 3.12; risk ratio [RR] 0.61 [95% CI 0.44% to 0.86%]). ED visits for infectious diseases and soft tissue injury were significantly lower for the cohort overall (RRs 0.58 0.51 [95% CIs 0.35% to 0.95% and 0.29% to 0.90%], respectively). Conclusion: Co-locating HCV treatment within comprehensive primary care and harm reduction services appears to have benefits beyond HCV, including a reduction in ED visits among women and a decrease in ED visits for soft tissue infections for all participants.
Background: The majority of new hepatitis C (HCV) cases occur among people who inject drugs. In recent years, multidisciplinary models of HCV treatment have emerged that demonstrate successful treatment outcomes for this population, as well as broad positive individual- and system-level impacts. Our objective was to evaluate changes in health care use among a cohort of people living with HCV before and after engagement with one such program. Methods: Program data were uniquely linked to provincial health administrative databases. Rates of emergency department (ED) visits and hospital admissions of clients from 2011 through 2015 (N = 103) were evaluated using linkages with administrative data for the 2 years before and after program initiation. Data were evaluated using negative binomial regression models with a covariance structure to account for within-individual correlations. Results: Of participants, 72.8% were men (mean age 47 years), and 38% experienced high rates of physical and mental health comorbidity (Aggregated Diagnosis Group score ≥10). Female clients had significantly fewer ED visits 2 years after program initiation (5.04 versus 3.12; risk ratio [RR] 0.61 [95% CI 0.44% to 0.86%]). ED visits for infectious diseases and soft tissue injury were significantly lower for the cohort overall (RRs 0.58 0.51 [95% CIs 0.35% to 0.95% and 0.29% to 0.90%], respectively). Conclusion: Co-locating HCV treatment within comprehensive primary care and harm reduction services appears to have benefits beyond HCV, including a reduction in ED visits among women and a decrease in ED visits for soft tissue infections for all participants.
Keywords:
community-based treatment models; emergency department use; health administrative data; health care models; hepatitis C; social determinants of health; substance use
Authors: Kate Mason; Zoë Dodd; Mary Guyton; Paula Tookey; Bernadette Lettner; John Matelski; Sanjeev Sockalingam; Jason Altenberg; Jeff Powis Journal: Int J Drug Policy Date: 2017-06-12
Authors: Kate Mason; Zoë Dodd; Sanjeev Sockalingam; Jason Altenberg; Christopher Meaney; Peggy Millson; Jeff Powis Journal: Int J Drug Policy Date: 2015-04-29
Authors: Ingrid A Binswanger; Traci A Takahashi; Katharine Bradley; Timothy H Dellit; Kathryn L Benton; Joseph O Merrill Journal: J Stud Alcohol Drugs Date: 2008-11 Impact factor: 2.582
Authors: Maryam Alavi; Jesse D Raffa; Gregory D Deans; Calvin Lai; Mel Krajden; Gregory J Dore; Mark W Tyndall; Jason Grebely Journal: Liver Int Date: 2013-11-20 Impact factor: 5.828